Cargando…

PB1971: FREQUENCY AND CHARACTERISTICS OF DEL(6Q) IN PATIENTS WITH MULTIPLE MYELOMA FROM LATIN-AMERICAN COUNTRIES. A REAL-WORLD STUDY

Detalles Bibliográficos
Autores principales:	Stella, F., Leone, P., Pedrazzini, E., Galvano, C., Zurita, S., Coccé, M., Gallego, M., Schultz, N., Alfonso, G., Canelos Moreno, J., Noboa, A., Huamán Garaicoa, F., Paz y Miño, C., Ziembar, M., Ochoa, P., Duarte, P., Quatrin, M., Colombi Martínez, F., Fernández, D., Cugliari, S., Uturbey, F., Peña, C., Slavutsky, I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431594/ http://dx.doi.org/10.1097/01.HS9.0000850720.49410.b7

Ejemplares similares

PB1865: SINGLE-COUNTRY, MULTICENTER, RETROSPECTIVE, OBSERVATIONAL, DESCRIPTIVE COHORT STUDY OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH VENETOCLAX IN ARGENTINA (VENARG).
por: Pagano Vilar, C., et al.
Publicado: (2022)

PB2200: CLONAL HEMATOPOIESIS AT THE CROSSROADS OF INFLAMMATORY BOWEL DISEASES AND HEMATOLOGICAL MALIGNANCIES: A BIOLOGICAL LINK?
por: Cumbo, C., et al.
Publicado: (2022)

PB2103: CAN WE ACCURATELY PREDICT SURVIVAL IN DIFFUSE LARGE B CELL LYMPHOMA IN THE RITUXIMAB ERA? RETROSPECTIVE COMPARISON OF IPI, AAIPI, R-IPI AND NCCN-IPI
por: Chorão, P., et al.
Publicado: (2022)

PB1840: MONOCENTRIC EXPERIENCE OF VENETOCLAX-BASED REGIMENS FOR ACUTE MYELOID LEUKEMIA
por: Sciumè, M., et al.
Publicado: (2022)

PB2260: CIDOFOVIR FOR THE TREATMENT OF ADENOVIRUS INFECTION IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): A SINGLE CENTER EXPERIENCE
por: Cacace, F., et al.
Publicado: (2022)

PB2015: YOUNG ADULTS WITH MULTIPLE MYELOMA – A SINGLE CENTER EXPERIENCE
por: Dos Santos Marques, I., et al.
Publicado: (2022)

PB2270: CLEARANCE OF PERSISTENT SARS-COV2 INFECTION WITH ANTIBODY CONTAINING PLASMA IN LEUKEMIA AND LYMPHOMA PATIENTS
por: Janssen, M., et al.
Publicado: (2022)

PB2237: HEMATIMETRIC DETECTION OF THE TRIPLICATION OF ALPHA-GLOBIN GENES. THE IMPORTANCE OF YOUR DIAGNOSIS
por: Ropero, P., et al.
Publicado: (2022)

PB1827: ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
por: Marques, I., et al.
Publicado: (2022)

PB2106: REDUCTION OF METHOTREXATE (MTX) LEVELS AFTER GLUCARPIDASE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT RISK OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT WHO RECEIVE HDMTX: PHASE 2
por: De La Fuente, A., et al.
Publicado: (2022)

PB1867: PURINE ANALOGS ON HAIRY CELL LEUKAEMIA TREATMENT
por: Gomes, G., et al.
Publicado: (2022)

PB2340: INFLUENCE OF INITIAL CLINICAL FEATURES IN THERAPEUTIC DECISIONS AND DIAGNOSTIC PROCESS OF ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA. A REAL WORLD EXPERIENCE
por: Bolea, L., et al.
Publicado: (2022)

PB2117: TEN-YEAR SINGLE CENTER EXPERIENCE TREATING PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: CAN RADIOTHERAPY BE OMITTED?
por: Goncalves, I. L., et al.
Publicado: (2022)

PB1971: A PHASE 1 MULTICENTER OPEN-LABEL DOSE-ESCALATION AND DOSE-EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, EFFICACY OF HS-10382 (TERN-70) IN CHRONIC MYELOID LEUKEMIA PATIENTS
por: LI, Weiming, et al.
Publicado: (2023)

PB2238: ΒETA-THALASSEMIA INTERMEDIA: INTERACTION OF ΑLPHA-GLOBIN GENE TRIPLICATION WITH ΒETA-THALASSEMIA HETEROZYGOUS IN SPAIN
por: Ropero, P., et al.
Publicado: (2022)

PB2307: A MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ROMIPLOSTIM PLUS DEXAMETHASONE VS DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED PRIMARY IMMUNE THROMBOCYTOPENIA
por: Mingot Castellano, M. E., et al.
Publicado: (2022)

PB2044: TRIAL IN PROGRESS: OBSERVATIONAL STUDY IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED IN ITALY WITH MIDOSTAURIN (OVIDIO)
por: Grifoni, F. I., et al.
Publicado: (2022)

PB1805: INSIGHTS FROM ORAL AZACITIDINE EARLY ACCESS PROGRAM IN FRANCE: PATIENT POPULATION WITH ACUTE MYELOID LEUKEMIA RECEIVING ORAL-AZA FOR MAINTENANCE OF COMPLETE REMISSION AFTER INDUCTION CHEMOTHERAPY
por: Raffoux, E., et al.
Publicado: (2022)

PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS
por: Bruzzese, A., et al.
Publicado: (2022)

PB1968: EPIGENETIC AND GENETIC INVESTIGATION OF SOCS-1 GENE IN PATIENTS WITH MULTIPLE MYELOMA
por: Serin, I., et al.
Publicado: (2022)

PB2115: TRIAL IN PROGRESS: A RANDOMIZED PHASE II STUDY OF MB-CART2019.1 COMPARED TO STANDARD OF CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION
por: Borchmann, P., et al.
Publicado: (2022)

PB2265: OUTCOMES OF COVID-19 INFECTION IN PATIENTS WITH B AND PLASMA CELL MALIGNANCIES DURING THE THIRD WAVE IN ARGENTINA: A SINGLE CENTER EXPERIENCE
por: Gelo, O., et al.
Publicado: (2022)

PB2239: DOES SIZE MATTER? THREE NEW DELETIONS IN THE HBB GENE CAUSE Β0-THALASSEMIA
por: Ropero, P., et al.
Publicado: (2022)

PB2235: COMPLETE DELETION OF THE CACCC BOX OF THE HBB GENE PROMOTER: A NEW MECHANISM LEADING TO A SILENT PHENOTYPE OF BETA THALASSEMIA
por: Mondesert, E., et al.
Publicado: (2022)

PB2398: BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASIA IN 2 CENTERS OF BOGOTÁ – COLOMBIA: THE LARGEST CASE SERIES IN LATIN AMERICA
por: Cynthia Fuentes-Lacouture, Maria, et al.
Publicado: (2023)

PB1892: IMATINIB RESISTANCE: THE ROLE OF PHARMACOGENETIC VARIABILITY IN A SOUTH AFRICAN COHORT
por: De Long, C., et al.
Publicado: (2022)

PB1886: LONG-TERM TRENDS IN THE LOSS OF LIFE EXPECTANCY AFTER A DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA: A POPULATION-BASED STUDY IN THE NETHERLANDS, 1989-2018
por: Van Der Straten, L., et al.
Publicado: (2022)

PB1815: T(8;16)(P11;P13): A RARE CASE OF ACUTE MYELOID LEUKEMIA
por: Cuccurullo, R., et al.
Publicado: (2022)

PB1760: AZACITIDINE AS TREATMENT OF KMT2A INFANT ACUTE LYMPHOBLASTIC LEUKEMIA: SINGLE CENTER EXPERIENCE
por: Giagnuolo, G., et al.
Publicado: (2022)

PB2161: CHARACTERISTICS OF AGGRESSIVE B-CELL LYMPHOMAS WITH MYC REARRANGEMENT
por: Ortuzar Pasalodos, A., et al.
Publicado: (2022)

PB1831: UTILITY OF FLT3 INHIBITORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND T(6;9)(P22;Q34)
por: Ong, F., et al.
Publicado: (2022)

PB1995: SAFETY OF SUBCUTANEOUS DARATUMUMAB IN MULTIPLE MYELOMA: A RETROSPECTIVE MULTI-CENTER REAL LIFE EXPERIENCE
por: De Novellis, D., et al.
Publicado: (2022)

PB2287: END OF LIFE TRANSFUSIONS IN PATIENTS WITH AN ONCOLOGICAL DIAGNOSIS
por: Duque, L., et al.
Publicado: (2022)

PB1945: CLINICAL AND MOLECULAR CHARACTERISTICS OF CHILDREN WITH DIAMOND-BLACKFAN ANEMIA (DBA): A SINGLE CENTER EXPERIENCE IN ARGENTINA
por: Mininni, M. F., et al.
Publicado: (2022)

PB1752: ANALYSIS OF HLA-PEPTIDE BINDING POCKETS IN PATIENTS WITH ACUTE LEUKEMIA UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION
por: Boukouaci, W., et al.
Publicado: (2022)

PB2028: TREATING MULTIPLE MYELOMA IN A RESOURCE-LIMITED SETTING: REAL-WORLD OUTCOMES
por: Martinez, G., et al.
Publicado: (2022)

PB2100: MANAGEMENT OF RELAPSED / REFRACTORY (R/R) B-CELL NON HODGKIN LYMPHOMA (B-NHL) WITH ANTI-CD20XCD3 BISPECIFIC ANTIBODY GLOFITAMAB. A SINGLE CENTER EXPERIENCE.
por: Giatra, C., et al.
Publicado: (2022)

PB1942: HEPATIC MANIFESTATIONS OF CHILDHOOD HEMOPHAGOCYTIC LYMPHOHISTOCYTOSIS
por: El Sayed, M., et al.
Publicado: (2022)

PB1862: BRUIN CLL-313: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS BENDAMUSTINE+RITUXIMAB IN UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (TRIAL IN PROGRESS)
por: Jurczak, W., et al.
Publicado: (2022)

PB2125: LYMPHOMATOID PAPULOSIS-LIKE (LYP-LIKE) AFTER BRENTUXIMAB VEDOTIN-CHP (BV-CHP) TREATMENT FOR ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)
por: Lopez Pereira, P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i2q9qh04buic5jfvl5r9hdvns5